Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Products under Development by Stage of Development | 8 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Products under Development by Therapy Area | 9 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Products under Development by Indication | 10 | 2 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Products under Development by Companies | 14 | 3 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Companies Involved in Therapeutics Development | 23 | 3 |
| FibroGen, Inc. | 23 | 1 |
| ProMetic Life Sciences Inc. | 24 | 1 |
| RXi Pharmaceuticals Corporation | 25 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Drug Profiles | 26 | 22 |
| Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR Drug Profile | 26 | 2 |
| OLX-101 Drug Profile | 28 | 1 |
| OLX-201 Drug Profile | 29 | 1 |
| pamrevlumab Drug Profile | 30 | 6 |
| PBI-4050 Drug Profile | 36 | 5 |
| RXI-109 Drug Profile | 41 | 6 |
| RXI-209 Drug Profile | 47 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Dormant Projects | 48 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Discontinued Products | 49 | 1 |
| Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Featured News &Press Releases | 50 | 13 |
| Jun 09, 2016: ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Associations upcoming annual meeting | 50 | 1 |
| May 18, 2016: Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis | 51 | 1 |
| Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model | 51 | 1 |
| Apr 26, 2016: ProMetic PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial | 52 | 1 |
| Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference | 53 | 1 |
| Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 | 54 | 1 |
| Apr 14, 2016: ProMetic confirms PBI-4050 Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells | 55 | 1 |
| Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications | 55 | 1 |
| Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference | 56 | 1 |
| Mar 22, 2016: ProMetic confirms PBI-4050 positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes | 57 | 1 |
| Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications | 57 | 1 |
| Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis | 58 | 1 |
| Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer | 59 | 1 |
| Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular | 60 | 2 |
| Dec 14, 2015: Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication | 62 | 1 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |